Evidence map›Paper›PMID 40924794›Full record

Observational studyHepatology (Baltimore, Md.)2026

Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study.

Srinivasan Dasarathy, Wanzhu Tu, Nicole Welch, Samer Gawrieh, Yunpeng Yu, Qing Tang, Carla Kettler, Arun J Sanyal, Gyongyi Szabo, Vijay H Shah and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Hepatology (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Comparison of Factors Associated With 30-Day and 90-Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Srinivasan DasarathyDepartment of Gastroenterology and Hepatology, and Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Wanzhu TuDepartment of Biostatistics and Health Data Science, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Nicole WelchDepartment of Gastroenterology and Hepatology, and Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Samer GawriehDepartment of Biostatistics and Health Data Science, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Yunpeng YuDepartment of Biostatistics and Health Data Science, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Qing TangDepartment of Biostatistics and Health Data Science, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Carla KettlerDepartment of Biostatistics and Health Data Science, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Arun J SanyalDepartment of Gastroenterology, Virginia Commonwealth University, Richmond, Virginia, USA.
Gyongyi SzaboDepartment of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Vijay H ShahDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Ramon BatallerClinc Barcelona, Barcelona, Spain.
Laura E NagyDepartment of Gastroenterology and Hepatology, and Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Craig J McClainDepartment of Medicine, University of Louisville, Louisville, Kentucky, USA.ORCID 0000-0002-7219-8939
Naga ChalasaniDepartment of Biostatistics and Health Data Science, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Thomas KerrDepartment of Gastroenterology and Hepatology, UT Southwestern, Dallas, Texas, USA.
Mack C MitchellDepartment of Gastroenterology and Hepatology, UT Southwestern, Dallas, Texas, USA.
for AlcHepNet Investigators

Funding

Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Indiana University Data Coordinating CenterU24AA026969 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI SAMER GAWRIEH, WANZHU TU · 2018 to 2026
$20.2M
Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2016 to 2026
$19.6M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN · 2016 to 2026
$17.9M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Fabio Cominelli · 2015 to 2026
$15.6M
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical CenterU01AA026976 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy, David Streem · 2018 to 2026
$3.2M
Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical CenterU01AA026975 · NIAAA · UT SOUTHWESTERN MEDICAL CENTER · PI E SHERWOOD BROWN, Mack Clarence Mitchell · 2018 to 2026
$3.0M
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Virginia Commonwealth UniversityU01AA026979 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Juan Pablo Arab, FREDERICK Gerard MOELLER · 2018 to 2026
$2.9M
Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitisR01AA028190 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, NAGY, LAURA E. · 2020 to 2024
$2.8M
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress responseR01DK113196 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, HATZOGLOU, MARIA · 2018 to 2021
$2.3M
Novel therapeutics for alcoholic hepatitis - Cleveland Translational ComponentU01AA021890 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2012 to 2017
$1.6M
Mechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01GM119174 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2017 to 2020
$1.2M
CSRD VA I01 CX002219NIAAA NIH HHS K08 AA028794NIAAA NIH HHS P50 AA024333NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R01 AA028190NIAAA NIH HHS R21 AA022742NIAAA NIH HHS U01 AA021890NIAAA NIH HHS U01 AA026975NIAAA NIH HHS U01 AA026976NIAAA NIH HHS U01 AA026979NIAAA NIH HHS U01 AA026980NIAAA NIH HHS U24 AA026969NIDDK NIH HHS P30 DK097948NIDDK NIH HHS R01 DK113196NIDDK NIH HHS R01 DK133905NIGMS NIH HHS R01 GM119174
6 · The paper itself

Abstract

BACKGROUND

aimsThe clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes do not capture the added risk of return to drinking. We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH. APPROACH

resultsA cohort of 1127 participants: 712 AH patients, 256 heavy drinking controls without clinically evident liver disease, and 159 healthy controls, were prospectively followed for 6 months at 8 United States centers as part of the Alcoholic Hepatitis Network (AlcHepNet) consortium. Outcomes included mortality and a composite endpoint (AlcHepNet composite index) that included death, liver transplantation, hepatic decompensation (new onset/worsening ascites, HE, variceal bleeding), liver-related hospital admission, MELD increase ≥5, and return to drinking. Of 712 AH patients (age 45±10.7 y; 59.1% male), 558 (79.0%) had severe and 148 (21.0%) had moderate AH, 232 (32.5%) died, and 86 (12.1%) underwent liver transplantation. Mortality rates in moderate AH and severe AH were 0.7% versus 17.2% (30 d), 3.4% versus 26.5% (90 d), and 8.8% versus 30.5% (180 d), respectively (all p <0.001). Composite liver/alcohol use events were noted in 459 (64.5%) AH patients. Higher MELD score, lower mean arterial pressure, and baseline leukocytosis were associated with higher 90-day mortality in AH (all p <0.05). College education and higher ALP were associated with lower mortality. Heavy drinking controls had low mortality (n=3; 1.2%).

conclusionsThis large observational study showed a high incidence of composite liver and alcohol-use events within 6 months, reiterating the need for early interventions.

Indexed as

Hepatitis, AlcoholicAdultDisease ProgressionFemaleHumansLiver TransplantationMaleMiddle AgedProspective StudiesSeverity of Illness IndexUnited Statesalcohol-associated hepatitiscomposite eventmulticenteroutcomesprospective

Identifiers

PMID40924794
PMCPMC12672022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.